Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.
Continue reading this article with a Barron’s subscription.
View Options
2023-12-26 11:19:00
All news and articles are copyrighted to the respective authors and/or News Broadcasters. VIXC.Com is an independent Online News Aggregator
Read more from original source here…
2 min read
2 min read
2 min read
2 min read
